Eindhoven and Nijmegen, 10 December 2025 – ECFG, together with a Dutch co-investor specialized in medical technology, is investing in NBCL, a fast-growing scale-up in surgical point-of-care diagnostics. NBCL’s management team and existing shareholders are also participating in the financing round.

The investment enables NBCL to meet growing international demand, strengthen its regulatory position, and prepare for market entry in the United States. This marks the sixth investment by ECFG Ventures III, which focuses on technology-driven companies with strong international scaling potential.

Innovation in the operating room: real-time decision support during parathyroid surgery

NBCL develops, manufactures, and commercializes a solution that provides surgeons with critical diagnostic information within minutes during surgery. The technology is used in parathyroid procedures, where rapid insight is required to determine whether the intervention has been fully successful. This real-time feedback helps reduce waiting lists and operating times, lowers the number of repeat surgeries, and enables more efficient use of operating room capacity.

For patients, this results in less surgical trauma, shorter hospital stays, and a higher likelihood of successful treatment in a single procedure. At the same time, it contributes to lower healthcare costs, reduced workload for healthcare professionals, and more accessible and future-proof healthcare.

The solution addresses a clear need in hospitals: faster clinical decision-making, lower costs, and improved patient safety. More than 100 hospitals across EMEA are already using the platform. In the United States, the first clinical studies have started as part of the regulatory approval pathway.

Strong investor base for the next growth phase

ECFG is investing through its Ventures III fund, which supports companies with capital, hands-on scale-up expertise, and a strong network within the enabling technologies sector.
The co-investor adds complementary experience in industrial scaling and quality management within highly regulated markets.

“NBCL fits perfectly within our investment focus: enabling technologies that can accelerate existing markets,” said Leo van Schijndel, Director Transactions at ECFG. “Strong demand in Europe and the first steps toward the U.S. market highlight the company’s international potential.”

NBCL sees growth accelerate

“Hospitals are increasingly recognizing the value of direct intraoperative diagnostics,” said Herbert Torfs, CEO of NBCL. “Our fast and sensitive PTH test supports surgeons during parathyroid procedures with information that was previously only available after surgery. This makes operations demonstrably safer and more efficient, while helping hospitals make better use of their capacity.

International demand is growing rapidly. In Europe, we see increasing adoption of our platform, and in the United States the first clinical studies are already underway. This financing allows us to scale our production capacity, further strengthen our quality and regulatory framework, and accelerate our global rollout. With the strengthened investor base, we can significantly accelerate our mission: better and more efficient care through rapid intraoperative diagnostics.”

More information

ECFG
Leo van Schijndel – Director Transactions
info@ecfg.nl | +31 40 295 0313

NBCL
Herbert Torfs, PhD – CEO & Commercial Director
Herbert@nbcl.nl | +32 473 593 236